Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 5/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 5/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 5/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | PRKDC | P78527 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358478 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL29676506 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL734208 | 0.94 | PIK3CD (0.88) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL733123 | 0.94 | PIK3CD (0.88) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL6519357 | 0.93 | PIK3CD (0.87) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL733780 | 0.93 | PIK3CD (0.86) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL733167 | 0.93 | PIK3CD (0.86) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL27899479 | 0.92 | PIK3CD (0.85) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL13133464 | 0.91 | PIK3CD (0.84) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL732871 | 0.91 | PIK3CD (0.84) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2916868-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS S A (CH) | 2022-05-11 | — | — | EP | claimed |
| US-11304939-B2 | Methods for treating oral cancers | CHANG GUNG UNIVERSITY (TW) | 2022-04-19 | — | — | US | claimed |
| CN-113667747-A | Method for treating oral cancer | 长庚大学 | 2021-11-19 | — | — | CN | claimed |
| US-11065236-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2021-07-20 | — | — | US | claimed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| CN-111904962-A | Pharmaceutical composition containing PDE4 inhibitor and PI3 or dual PI 3-gamma kinase inhibitor | 理森制药股份公司 | 2020-11-10 | — | — | CN | claimed |
| US-20200237735-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A P13 DELTA OR DUAL P13 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| US-10058539-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2018-08-28 | — | — | US | claimed |
| US-20170319558-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2017-11-09 | — | — | US | claimed |
| US-9737521-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2017-08-22 | — | — | US | claimed |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION | 2004-12-30 | — | — | US | claimed |
| US-6800620-B2 | CONTACTING LEUKOCYTES, OSTEOCLASTS WITH AN ENZYME INHIBITORS, A 9H-PURIN-3H-QUINAZOLIN-4-ONE DERIVATIVES, TREATING BONE-RESORPTION DISORDER, ANTIPROLIFERATIVE AGENTS TREATING LEUKEMIA CELLS | ICOS | 2004-10-05 | — | — | US | claimed |
| EP-1438052-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL−INOSITOL 3−KINASE DELTA | ICOS CORPORATION (US) | 2004-07-21 | — | — | EP | claimed |
| JP-2003531209-A | — | — | 2003-10-21 | — | — | JP | claimed |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION | 2003-10-16 | — | — | US | claimed |
| CN-1440408-A | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORP (US) | 2003-09-03 | — | — | CN | claimed |
| WO-2003035075-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-05-01 | — | — | WO | claimed |
| EP-1278748-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | claimed |
| WO-2001081346-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2001-11-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | PIK3CD 3/4885PIK3R1 9/4885PIK3CB 10/4885 |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 18/4885PIK3CB 5/4885 |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 7/4885PIK3CB 4/4885 |
| US-20170319558-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | PIK3CD, PIK3R4, PIK3CG | PIK3CD 1/4885PIK3R1 21/4885PIK3CB 11/4885 |
| US-20200237735-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A P13 DELTA OR DUAL P13 DELTA-GAMMA KINASE INHIBITOR | PDE4A, PDE12, PDE4B | PIK3CD 9/4885PIK3R1 50/4885PIK3CB 29/4885 |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CB 4/4885 |
| US-11065236-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | PIK3CD, PIK3R4, PIK3CG | PIK3CD 1/4885PIK3R1 21/4885PIK3CB 11/4885 |
| US-10058539-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | PIK3CD, PIK3R4, PIK3CG | PIK3CD 1/4885PIK3R1 21/4885PIK3CB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.